Pharma & biotech

Pharmacosmos predicts record financial year after launches in US and China

The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.
Tobias Sidelmann Christensen, Vice President and Chief Operating Officer at Pharmacosmos (right) and his father Lars Christensen, who is CEO of the company. | Photo: Pharmacosmos / PR
Tobias Sidelmann Christensen, Vice President and Chief Operating Officer at Pharmacosmos (right) and his father Lars Christensen, who is CEO of the company. | Photo: Pharmacosmos / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

Pharmacosmos has lit a fire under its dream of becoming an international company by establishing a presence in the US and China through subsidiaries and launching its main product (called Monoferric in the US and Monofer in China) on both markets.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs